Article
Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
European journal of gastroenterology & hepatology - 1 Dec 2010
Orlent Hans, Desombere Isabelle, Hansen Bettina, Van Vlierberghe Hans, Haagmans Bart, De Knegt Robert J, Schalm Solko W, Leroux-Roels Geert, Janssen Harry L A
Abstract excerpt
BACKGROUND: Early detection of nonresponders to hepatitis C therapy limits unnecessary exposure to treatment and its side-effects. A recent algorithm combining baseline anti-NS4a antibodies and on-treatment quantitative PCR identified nonresponders to a combination of interferon and ribavirin after 1 week of treatment. AIM: To validate a stopping rule based on baseline anti-NS4a antibody levels and early...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.